ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in Arthritis, Is Negatively Regulated by GRK3

D. Stephen Serafin1, Roman Timoshchenko1, Marcus W. McGinnis2 and Teresa K. Tarrant3, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina Sch of Med, Chapel Hill, NC, 3Medicine/Rheumatology, UNC School of Medicine, Chapel Hill, NC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: chemokines, inflammation and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chemokine-like receptor 1 (CMKLR1) is a G protein coupled receptor (GPCR) expressed by inflammatory monocytes that are pathogenic in human diseases such as psoriasis and lupus. Its cognate ligand, chemerin, is a chemoattractant for invading inflammatory cells and is present in the synovial lining of rheumatoid arthritis (RA), osteoarthritis (OA), and psoriatic arthritis (PsA) patients.  In OA, chemerin is thought to contribute to both the extracellular matrix breakdown of cartilage as well as joint inflammation.

CMKLR1 is a newly discovered GPCR, which as a class of receptors are phosphorylated by G-protein receptor kinases (GRKs) to turn off GPCR signaling. Due to the significant role of chemerin/CMKLR1 interaction in human inflammatory arthritis, we chose to examine the unknown regulatory mechanism of CMKLR1 by GRKs. 

Methods: Isoforms GRK3 and GRK2 were separately knocked down in human monocytic THP-1 cells using shRNA and confirmed via quantitative real time PCR. Migration to chemerin (100 ng/mL) was measured by fluorescence emission through the BD Falcon 96-Multiwell Insert System or flow cytometry through 5 µM Transwells over 3 hrs.

A modified Tango assay was used to measure β-arrestin recruitment to CMKLR1.  HTLA cells were over expressed with CMKLR1 and GRK2 or GRK3 via calcium phosphate precipitation. Cells were stimulated with 1 µM of chemerin and after 24 hours, luminescence was measured on a Trilux plate reader. 

Results: CMKLR1 recruits β-arrestin in a ligand-dependent dose response.  β-arrestin recruitment to CMKLR1 is mediated preferentially by GRK3 as compared to GRK2.  THP-1 cells deficient in GRK3 showed enhanced chemotaxis to chemerin when compared to control cells.

Conclusion: We conclude that the chemerin/ CMKLR1 axis plays an important role in targeting monocytes to sites of inflammation and is negatively regulated by GRK3.


Disclosure:

D. S. Serafin,
None;

R. Timoshchenko,
None;

M. W. McGinnis,
None;

T. K. Tarrant,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chemokine-like-receptor-1-cmklr1-a-g-protein-coupled-receptor-expressed-on-proinflammatory-monocytes-in-arthritis-is-negatively-regulated-by-grk3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology